BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Avinger, Inc. Raises $33 Million in Series D Financing


7/10/2012 9:12:37 AM

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Avinger, Inc. announces today the closing of a $33 million Series D funding round. Existing major investors participated in the round, with new investors alone contributing over $11 million. Avinger is a medical device manufacturer of innovative, multi-functional catheters for treating patients with Peripheral Artery Disease (PAD), a disease that causes upwards of 150,000 leg amputations a year.

“We are very pleased with the outcome of our Series D capital raise and plan to invest heavily in accelerating Avinger’s growth. While using these latest funds to facilitate worldwide sales of our existing product lines, we’ll continue planning for clinical trials involving more products that incorporate intravascular imaging,” said Kenneth Novack, Chairman of Avinger’s Board of Directors. “We are at the forefront of fighting this silent epidemic that currently impacts 8 to 12 million adults in the U.S. alone.”

This round comes on the heels of the completion of Avinger’s CONNECT II global clinical trial for Ocelot, the first-ever crossing catheter with integrated real-time intravascular imaging. “Ocelot was designed to enable more informed treatment decisions, and the more information a physician has available during a procedure, the better we can help treat those patients,” said Dr. John B. Simpson, CEO and Founder of Avinger. Currently CE marked and commercially available in Europe, the company expects to submit a 510(k) to the FDA for Ocelot later this year.

The new funds will also support the company’s continued R&D efforts around Wolverine, the first-ever peripheral atherectomy catheter that also incorporates intravascular imaging technology using Optical Coherence Tomography (OCT).

Avinger’s global product portfolio has helped physicians treat more than 10,000 patients suffering from PAD.

JMP Securities acted as financial advisor on the transaction.

About Avinger

Founded in 2007 by renowned cardiologist and medical device entrepreneur Dr. John B. Simpson, Avinger develops next-generation catheter-based technologies for the treatment of peripheral artery disease (PAD). Leveraging core competencies in medical device catheter engineering and intravascular Optical Coherence Tomography (OCT), Avinger markets Wildcat and Kittycat catheters, and in 2011 received CE Mark to market Ocelot, the first ever real-time OCT crossing catheter. www.avinger.com.

Contact:

Avinger PR

Deborah Getz, +1-650-241-7900

dgetz@avinger.com

or

Press Inquiries:

Mortar PR

Allyson Stinchfield, +1-415-772-9907 ext. 120

allyson@mortaragency.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->